A robotic radiosurgery system in development for the noninvasive treatment of atrial fibrillation.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
ReWalk™
A wearable, computer-controlled, motorized exoskeleton designed to enable paraplegics to independently conduct routine ambulatory functions.
DaTSCAN™ (123-I-Ioflupane, 123-I-FP-CIT)
An intravenous, neuroimaging, radiopharmaceutical used with single photon emission computed tomography as an objective adjunct to the clinical diagnosis of neurodegeneration in patients with movement disorders.
ProACT™ (Adjustable Continence Therapy for the Prostate)
Implantable device to treat severe stress urinary incontinence after prostate surgery.
PTMA® (Percutaneous Transvenous Mitral Annuloplasty) System
A coronary sinus annuloplasty device for the treatment of functional mitral regurgitation that includes varied rods placed temporarily in the coronary sinus for sizing, and then exchanged for a permanent customized implant.
Ampyra™ (Dalfampridine, Formerly Fampridine-SR)
An oral potassium channel blocker being developed to improve walking ability in people with multiple sclerosis.
Masitinib (AB1010)
An orally administered, novel protein tyrosine kinase inhibitor proposed for the treatment of adult patients with active rheumatoid arthritis refractory to standard therapy.
Restore Suturing System™
An endoluminal suturing device used in an incisionless restrictive procedure to treat obesity.
Denosumab (Possibly Xgeva™) for Skeletal Complications Due to Cancer
A once-monthly injected, antiresorptive biologic agent that is being developed to manage skeletal complications due to multiple myeloma or bone metastases from solid tumors.
ACT™ (Adjustable Continence Therapy)
Implantable device to treat female stress urinary incontinence refractory to more conservative interventions or after one or more failed incontinence surgeries.